JP2016514159A5 - - Google Patents

Download PDF

Info

Publication number
JP2016514159A5
JP2016514159A5 JP2016502219A JP2016502219A JP2016514159A5 JP 2016514159 A5 JP2016514159 A5 JP 2016514159A5 JP 2016502219 A JP2016502219 A JP 2016502219A JP 2016502219 A JP2016502219 A JP 2016502219A JP 2016514159 A5 JP2016514159 A5 JP 2016514159A5
Authority
JP
Japan
Prior art keywords
alkyl
compound
compound according
heteroaryl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502219A
Other languages
English (en)
Japanese (ja)
Other versions
JP6276378B2 (ja
JP2016514159A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/026710 external-priority patent/WO2014151945A1/en
Publication of JP2016514159A publication Critical patent/JP2016514159A/ja
Publication of JP2016514159A5 publication Critical patent/JP2016514159A5/ja
Application granted granted Critical
Publication of JP6276378B2 publication Critical patent/JP6276378B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502219A 2013-03-14 2014-03-13 ヒストンデメチラーゼ阻害剤 Expired - Fee Related JP6276378B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361783563P 2013-03-14 2013-03-14
US61/783,563 2013-03-14
PCT/US2014/026710 WO2014151945A1 (en) 2013-03-14 2014-03-13 Histone demethylase inhibitors

Publications (3)

Publication Number Publication Date
JP2016514159A JP2016514159A (ja) 2016-05-19
JP2016514159A5 true JP2016514159A5 (enExample) 2017-02-16
JP6276378B2 JP6276378B2 (ja) 2018-02-07

Family

ID=51529949

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502219A Expired - Fee Related JP6276378B2 (ja) 2013-03-14 2014-03-13 ヒストンデメチラーゼ阻害剤

Country Status (7)

Country Link
US (5) US9133166B2 (enExample)
EP (1) EP2969007B1 (enExample)
JP (1) JP6276378B2 (enExample)
AU (1) AU2014236711A1 (enExample)
CA (1) CA2903081A1 (enExample)
ES (1) ES2731773T3 (enExample)
WO (1) WO2014151945A1 (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9133166B2 (en) 2013-03-14 2015-09-15 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
CA2954060A1 (en) 2014-07-03 2016-01-07 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1
US9896436B2 (en) 2014-09-16 2018-02-20 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EA201790502A1 (ru) * 2014-09-16 2017-10-31 Селджен Квонтисел Рисёрч, Инк. Ингибиторы гистоновых диметилаз
JP2016089002A (ja) * 2014-10-31 2016-05-23 出光興産株式会社 ベンゾフラノチオフェン骨格を有するモノマー及びポリマー、及びそのポリマーを用いた有機薄膜太陽電池材料
JP6889661B2 (ja) * 2015-01-09 2021-06-18 ジェネンテック, インコーポレイテッド 4,5−ジヒドロイミダゾール誘導体およびヒストンジメチラーゼ(kdm2b)インヒビターとしてのその使用
WO2016210292A1 (en) 2015-06-25 2016-12-29 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
US20190055212A1 (en) * 2016-02-16 2019-02-21 Stephen Gwaltney Histone demethylase inhibitors
WO2017161001A1 (en) 2016-03-15 2017-09-21 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
EP3436445B1 (en) * 2016-03-15 2023-09-06 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EP3246330A1 (en) 2016-05-18 2017-11-22 Istituto Europeo di Oncologia S.r.l. Imidazoles as histone demethylase inhibitors
ES2969239T3 (es) 2016-05-27 2024-05-17 Gilead Sciences Inc Combinación de ledipasvir y sofosbuvir para su uso en el tratamiento de infecciones por el virus de la hepatitis B en humanos
BR102017010009A2 (pt) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
ES2826748T3 (es) 2016-09-02 2021-05-19 Gilead Sciences Inc Derivados de 4,6-diamino-pirido[3,2-d]pirimidina como moduladores de receptores de tipo Toll
KR102268448B1 (ko) 2016-09-02 2021-06-22 길리애드 사이언시즈, 인코포레이티드 톨 유사 수용체 조정제 화합물
MA46535A (fr) 2016-10-14 2019-08-21 Prec Biosciences Inc Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b
CN106543092B (zh) * 2016-10-14 2019-05-17 华东师范大学 1,5-二芳香基-1,2,4-三氮唑类化合物及其制药用途
TWI868958B (zh) 2017-01-31 2025-01-01 美商基利科學股份有限公司 替諾福韋埃拉酚胺(tenofovir alafenamide)之晶型
JOP20180008A1 (ar) 2017-02-02 2019-01-30 Gilead Sciences Inc مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
EP3728283B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
WO2019160882A1 (en) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 2,2,─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
WO2019204609A1 (en) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
WO2019236766A1 (en) 2018-06-06 2019-12-12 Ideaya Biosciences, Inc. Methods of culturing and/or expanding stem cells and/or lineage committed progenitor cells using lactam compounds
BR112020026746A2 (pt) 2018-07-13 2021-03-30 Gilead Sciences, Inc. Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição.
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
CN112955435B (zh) 2018-10-24 2024-09-06 吉利德科学公司 Pd-1/pd-l1抑制剂
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
FI3873903T3 (fi) 2018-10-31 2024-03-26 Gilead Sciences Inc Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina
EP3934757B1 (en) 2019-03-07 2023-02-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
CA3129011C (en) 2019-03-07 2023-12-19 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
JP7237311B2 (ja) * 2019-06-06 2023-03-13 京都府公立大学法人 化合物、医薬組成物、kdm5c阻害剤及び抗うつ剤
MX2021015452A (es) 2019-06-25 2022-02-11 Gilead Sciences Inc Proteinas de fusion flt3l-fc y metodos de uso.
WO2021011891A1 (en) 2019-07-18 2021-01-21 Gilead Sciences, Inc. Long-acting formulations of tenofovir alafenamide
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
KR20220074917A (ko) 2019-09-30 2022-06-03 길리애드 사이언시즈, 인코포레이티드 Hbv 백신 및 hbv를 치료하는 방법
DK4069729T3 (da) 2019-12-06 2025-04-07 Prec Biosciences Inc Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet
AR121620A1 (es) 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
JP7712352B2 (ja) 2020-08-07 2025-07-23 ギリアード サイエンシーズ, インコーポレイテッド ホスホンアミドヌクレオチド類似体のプロドラッグ及びその薬学的使用
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
EP4337223A1 (en) 2021-05-13 2024-03-20 Gilead Sciences, Inc. Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics
AU2022299051B2 (en) 2021-06-23 2025-03-13 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240025616A (ko) 2021-06-23 2024-02-27 길리애드 사이언시즈, 인코포레이티드 다이아실글리세롤 키나제 조절 화합물
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20250099113A (ko) 2022-09-09 2025-07-01 이노보 테라퓨틱스 인코포레이티드 CK1α 및 DUAL CK1α/GSPT1 분해 화합물
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3127900A (en) 1998-12-23 2000-07-31 Du Pont Pharmaceuticals Company Thrombin or factor xa inhibitors
AU3980602A (en) 2000-10-26 2002-06-03 Tularik Inc Antiinflammation agents
US20040127733A1 (en) 2002-10-31 2004-07-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg New beta-agonists, processes for preparing them and their use as pharmaceutical compositions
DE102004021779A1 (de) 2004-04-30 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
JP2009519998A (ja) 2005-12-19 2009-05-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング アミノアルコール誘導体の過活動膀胱の治療の為の使用
JP4388997B2 (ja) * 2006-09-05 2009-12-24 協和発酵キリン株式会社 イミダゾール誘導体
AU2008242720A1 (en) * 2007-04-20 2008-10-30 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
GB0818907D0 (en) * 2008-10-15 2008-11-19 Isis Innovation Histone lysine demethylase inhibitors
US20120101099A1 (en) * 2009-07-07 2012-04-26 Anthem Biosciences Private Limited Histone deacetylase inhibitors
CN102695708B (zh) 2009-11-10 2014-10-15 辉瑞大药厂 N1-吡唑并螺酮乙酰辅酶a羧化酶抑制剂
WO2011089995A1 (ja) * 2010-01-21 2011-07-28 公立大学法人名古屋市立大学 ヒドロキサム酸誘導体及びそれを用いたhdac8阻害剤
GB201112607D0 (en) * 2011-07-22 2011-09-07 Glaxo Group Ltd Novel compounds
CN102775368B (zh) * 2011-05-10 2016-08-17 上海驺虞医药科技有限公司 一类噻唑类化合物及其制备方法和用途
US9133166B2 (en) * 2013-03-14 2015-09-15 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
EA201790502A1 (ru) 2014-09-16 2017-10-31 Селджен Квонтисел Рисёрч, Инк. Ингибиторы гистоновых диметилаз

Similar Documents

Publication Publication Date Title
JP2016514159A5 (enExample)
JP2016501882A5 (enExample)
CY1123994T1 (el) Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4
CY1122279T1 (el) Ενωσεις ναφθυριδινης αναστολεις κινασης jak
JP2016503799A5 (enExample)
JP2017527590A5 (enExample)
JP2013537203A5 (enExample)
JP2016505614A5 (enExample)
JP2013532687A5 (enExample)
CY1118340T1 (el) Αναστολεις κινασης
BR112016015365A8 (pt) composto, composição farmacêutica e uso de um composto
JP2015024998A5 (enExample)
JP2015522045A5 (enExample)
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
JP2017508782A5 (enExample)
JP2018531941A5 (enExample)
JP2011529054A5 (enExample)
JP2011518833A5 (enExample)
JP2017501237A5 (enExample)
JP2013532130A5 (enExample)
JP2015199738A5 (enExample)
EA201691136A1 (ru) Производное на основе 1,2-нафтохинона и способ его получения
JP2014526533A5 (enExample)
CY1117688T1 (el) Ενωσεις τετραϋδροπυρρολοθειαζινης
JP2017538836A5 (enExample)